Rich Edwards
Chief Technology Officer Nuclide Therapeutics
Richard Edwards is Co-Founder and CTO of Nuclide Tx, where he leads radiochemistry, GMP manufacturing, and technical strategy for the development of next-generation radiopharmaceuticals. He has over a decade of experience in radiopharmaceutical development, with particular expertise in radiohalogen chemistry, spanning fluorine, iodine and astatine isotopes for cancer imaging and therapy. Richard completed his PhD in Radiochemistry at Cardiff University before holding research positions at the IECB, The Institute of Cancer Research, and King’s College London. His work has resulted in high-impact publications, patented technologies, successful licensing agreements, and more than £1.6 million in translational funding for theranostic programmes.
Seminars
- Evaluating where Actinium-225 offers meaningful clinical advantages over established beta-emitting radionuclides to maximise patient benefit
- Overcoming isotope supply, manufacturing and infrastructure constraints to enable sustainable clinical development and future commercialisation
- Optimising target selection, dosimetry and therapeutic index to improve efficacy while minimising off-target toxicity
- Preparing novel radiopharmaceutical technologies for successful GMP tech transfer and clinical manufacturing
- Lessons learned navigating analytical, CMC and operational challenges during technology transfer • Coordinating discovery, manufacturing and clinical teams to enable seamless progression into Phase I
- Key considerations for de-risking technology transfer while maintaining programme momentum
